Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$2.05
+12.0%
$1.26
$0.66
$3.00
$190.66M2.481.28 million shs2.96 million shs
Immuneering Corporation stock logo
IMRX
Immuneering
$4.13
-4.0%
$2.58
$1.00
$4.60
$148.62M0.382.59 million shs317,161 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.97
-2.6%
$12.75
$6.43
$27.38
$163.27M0.43159,496 shs91,806 shs
Pluri Inc. stock logo
PLUR
Pluri
$4.95
-8.5%
$4.85
$3.33
$7.13
$40.93M0.7920,870 shs6,705 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
0.00%+25.77%+60.16%+178.91%-22.35%
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-6.56%+49.10%+225.20%+252.99%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+7.99%+2.69%-3.43%+102.34%
Pluri Inc. stock logo
PLUR
Pluri
0.00%-6.78%+14.85%+26.11%-13.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.02 of 5 stars
3.53.00.00.00.01.70.6
Immuneering Corporation stock logo
IMRX
Immuneering
3.239 of 5 stars
3.32.00.00.02.55.00.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3154 of 5 stars
3.50.01.72.73.82.51.3
Pluri Inc. stock logo
PLUR
Pluri
2.9527 of 5 stars
3.55.00.00.00.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
3.00
Buy$8.50314.63% Upside
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25220.82% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50135.16% Upside
Pluri Inc. stock logo
PLUR
Pluri
3.00
Buy$12.00142.42% Upside

Current Analyst Ratings Breakdown

Latest PLUR, LFVN, CRBU, and IMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/2/2025
Pluri Inc. stock logo
PLUR
Pluri
Industrial Alliance Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
6/2/2025
Pluri Inc. stock logo
PLUR
Pluri
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
5/7/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/28/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $3.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.99M19.08N/AN/A$2.79 per share0.73
Immuneering Corporation stock logo
IMRX
Immuneering
$320K464.50N/AN/A$1.33 per share3.11
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.82$0.88 per share14.71$2.05 per share6.33
Pluri Inc. stock logo
PLUR
Pluri
$330K118.05N/AN/A$1.00 per share4.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.80N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Pluri Inc. stock logo
PLUR
Pluri
-$20.89M-$5.53N/AN/A-2,563.29%-4,191.91%-85.40%9/16/2025 (Estimated)

Latest PLUR, LFVN, CRBU, and IMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.40N/AN/AN/AN/AN/A
5/13/2025Q3 2025
Pluri Inc. stock logo
PLUR
Pluri
N/A-$0.94N/A-$0.94N/A$0.43 million
5/8/2025Q1 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/5/2025Q1 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.39%N/A26.09%3 Years
Pluri Inc. stock logo
PLUR
Pluri
N/AN/AN/AN/AN/A

Latest PLUR, LFVN, CRBU, and IMRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
7.63
7.63
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Pluri Inc. stock logo
PLUR
Pluri
51.65
4.81
4.81

Institutional Ownership

CompanyInstitutional Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Pluri Inc. stock logo
PLUR
Pluri
16.59%

Insider Ownership

CompanyInsider Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.28%
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Pluri Inc. stock logo
PLUR
Pluri
25.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.00 million85.30 millionOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Pluri Inc. stock logo
PLUR
Pluri
1507.87 million5.83 millionOptionable

Recent News About These Companies

Pluri Inc. reschedules 2025 annual meeting
Pluri: Fiscal Q3 Earnings Snapshot
Pluri Inc. acquires majority stake in Kokomodo Ltd.
Pluri acquires 71% stake in Kokomodo
Pluri’s immune cell expansion technologies gain patents

New MarketBeat Followers Over Time

Media Sentiment Over Time

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$2.05 +0.22 (+12.02%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.05 0.00 (0.00%)
As of 07/18/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$4.13 -0.17 (-3.95%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.15 +0.02 (+0.51%)
As of 07/18/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.97 -0.34 (-2.55%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$12.96 -0.01 (-0.04%)
As of 07/18/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Pluri stock logo

Pluri NASDAQ:PLUR

$4.95 -0.46 (-8.50%)
Closing price 07/18/2025 03:34 PM Eastern
Extended Trading
$4.66 -0.29 (-5.86%)
As of 07/18/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.